|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Metformin does not improve survival in patients with hepatocellular carcinoma显示文摘AIM:To assess whether metformin,which has a chemopreventive effect in chronic liver disease,has any chemotherapeutic effect in hepatocellular carcinoma.METHODS:This was a retrospective study of 701 patients with newly diagnosed hepatocellular carcinoma(HCC)seen between January 2005 and June 2011 at Mayo Clinic,Rochester,Minnesota.This patient cohort was a part of the global HCC BRIDGE study,which is a large longitudinal study of HCC determining the realworld experience of HCC characteristics,management and patient outcomes.We defined significant metformin exposure as continuation of this agent at least 90d beyond diagnosis of HCC,and compared survival of diabetic patients on metformin to diabetic patients not on metformin and non-diabetics.RESULTS:Our cohort was 72.9%male,with a mean±SD age of 62.6±12.3 years.The most common etiologies of liver disease were hepatitis C(34%),alcoholic liver disease(29%),fatty liver disease(15%)and hepatitis B(9%).By univariate analysis,using diabetics not on metformin as the reference group,diabetic patients with HCC on metformin had no survival advantage,with a HR(95%CI)of 1.0(0.8-1.3).Non-diabetic HCC patients also did not appear to have a survival advantage as compared to diabetic HCC patients not on metformin,as demonstrated by a HR(95%CI)of1.1(0.7-1.7).Diabetics on metformin beyond 90 d after HCC diagnosis had a longer median survival at 34.2 mo,as compared to 25.5 mo among diabetic patients who were not on metformin or had discontinued metformin within 90 d after HCC diagnosis.This finding was likely due to potential survival bias among those who lived long enough to receive metformin.CONCLUSION:Although the literature suggests a chemotherapeutic effect in other malignancies,our study demonstrates no survival benefit to the use of metformin in diabetic patients with HCC. | Mamatha Bhat Roongruedee Chaiteerakij William S Harmsen Cathy D Schleck Ju Dong Yang Nasra H Giama Terry M Therneau Gregory J Gores Lewis R Roberts | 2014 | World Journal of Gastroenterology2014，20，42： | 11 |
| 2 | Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models显示文摘AIM To assess the performance of BALAD, BALAD-2 and their component biomarkers in predicting outcome of hepatocellular carcinoma(HCC) patients after liver transplant.METHODS BALAD score and BALAD-2 class are derived from bilirubin, albumin, alpha-fetoprotein(AFP), Lens culinaris agglutinin-reactive AFP(AFP-L3), and des-gammacarboxyprothrombin(DCP). Pre-transplant AFP, AFP-L3 and DCP were measured in 113 patients transplanted for HCC from 2000 to 2008. Hazard ratios(HR) for recurrence and death were calculated. Univariate and multivariate regression analyses were conducted. C-statistics were used to compare biomarker-based to predictive models. RESULTS During a median follow-up of 12.2 years, 38 patients recurred and 87 died. The HRs for recurrence in patients with elevated AFP, AFP-L3, and DCP defined by BALAD cut-off values were 2.42(1.18-5.00), 1.86(0.98-3.52), and 2.83(1.42-5.61), respectively. For BALAD, the HRs for recurrence and death per unit increased score were 1.48(1.15-1.91) and 1.59(1.28-1.97). For BALAD-2, the HRs for recurrence and death per unit increased class were 1.45(1.06-1.98) and 1.38(1.09-1.76). For recurrence prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs. 0.64, 0.61, 0.53, and 0.53 for BALAD, BALAD-2, Milan, and UCSF, respectively. Similarly, for death prediction, the combination of three biomarkers had the highest c-statistic of 0.66 vs 0.65,0.61, 0.52, and 0.50 for BALAD, BALAD-2, Milan, and UCSF. A new model combining biomarkers with tumor size at the time of transplant(S-LAD) demonstrated the highest predictive capability with c-statistics of 0.71 and 0.69 for recurrence and death. CONCLUSION BALAD and BALAD-2 are valid in transplant HCC patients, but less predictive than the three biomarkers in combination or the three biomarkers in combination with maximal tumor diameter(S-LAD). | Nicha Wongjarupong Gabriela M Negron-Ocasio Roongruedee Chaiteerakij Benyam D Addissie Essa A Mohamed Kristin C Mara William S Harmsen J Paul Theobald Brian E Peters Joseph G Balsanek Melissa M Ward Nasra H Giama Sudhakar K Venkatesh Denise M Harnois Michael R Charlton Hiroyuki Yamada Alicia Algeciras-Schimnich Melissa R Snyder Terry M Therneau Lewis R Roberts | 2018 | World Journal of Gastroenterology2018，24，12： | 5 |
| 3 | 评估超高温灭菌奶安全和质量的2个重要参数显示文摘使用了一套电子程序表格,用于评估在连续热交换器中经过不同升温和降温处理后牛奶的安全和质量参数。安全参数包括致死率F0值、微生物灭活B*值;质量参数包括化学变化C*值、硫胺素损失量、乳果糖生成量、美拉德褐变及羟甲基糠醛值等。在牛奶中试加工车间中,利用升温和降温的温度变化数值可对牛奶的上述参数进行预测,温度范围为120~150℃,时间包括4、27和58 s。在同一中试车间按上述条件对牛奶进行加工,并选择一系列牛奶样品对该电子程序进行校正。结果表明,所有C*〈3的牛奶样品阿沙芬堡浊度都呈阳性。在乳果糖活化能等于122 k J/mol时,预测值和试验观测值一致性最好。最佳质量终产品对应的牛奶加工条件为135℃/10 s,此时B*=1.24,C*=0.55。在此条件下加工的牛奶与其它2个牛奶相比,感官特性与C*=1.5对应条件下加工的牛奶类似,但与C*=6对应条件下加工的牛奶不同。牛奶刚加工完成时,仅热处理非常强烈的样品有可见的褐变,若在≥30℃条件下存储,褐变会变得比较明显。该电子程序可以用来比较不同热处理模式下生产产品的特性;或作为一种手段,用于在升温和降温速率固定的情况下UHT设备运行条件的优化。 | 陈美霞 Browning E Lewis M Macdougall D | 2016 | 中国乳业2016，，5： | 3 |
| 4 | Expression, processing, and assembly of foot-and-mouth disease virus capsid structures in heterologous systems: induction of a neutralizing antibody resp- onse in guinea pigs 显示文摘 | Lewis S Morgan D Grubman M | 1991 | J Virol1991，65，12： | 1 |
| 5 | The ten command- ments of balanced scorecard implementation 显示文摘 | LEWY CLAUDE LEX D M | 1998 | Management Control and Accounting1998，，5： | 1 |
| 6 | Modelling through-soil transport of phosphorus to surface waters from livestock agriculture at the field and catchment scale 显示文摘 | MeGechan M B Lewis D R Hooda P S | 2005 | Science of the Total Environment2005，344，13： | 1 |
| 7 | Structure-function relations of heparin-mimetic sulphated xylan-oligosaccharides inhibition of Human Immunodeficiency Virus-1 infectivity in vitro显示文摘 | Stone A L Melton D J Lewis M S | 1998 | GlycoconjugateJournal1998，15，： | 1 |
| 8 | A universal dye for all fibers are disperse dyes capable of fulfilling this vision? 显示文摘 | Broadbent P J | 1997 | JSDC1997，113，： | 1 |
| 9 | The Production of Level Fast Dyeings on Wool with Nucleophilic Dyes and a Crosslinking Agent显示文摘 | Lewis D M Wang Y N | 1992 | JSDC1992，108，9： | 1 |
| 10 | Web space reconstruction with a M-V flap显示文摘 | LEWIS R C NORDYKE M D DUNCAN K H | 1988 | J Hand Surg Am1988，13，1： | 1 |
| 11 | Fracta] Surface of Proteins显示文摘 | Lewis M Rens D C | 1985 | Science1985，230，： | 1 |
| 12 | Complement activationcontributes to both glomerular and tubulointerstitial damagein adriamycin nephropathy in mice显示文摘 | Tumberg D Lewis M Moss J | 2006 | J Immunol2006，177，6： | 1 |
| 13 | Intercellular adhesion molecule expression in the evolving human cutaneous delayed hypersensitivity reaction 显示文摘 | Lewis RE Buchsbaum M Whitaker D | 1989 | J Invest Dermatol1989，93，5： | 1 |
| 14 | An intercomparison of sampling techniques for nicotine in indoor environments显示文摘 | Caka F M Eatough D J Lewis E A | 1994 | Environmental Science and Technology1994，24，8： | 1 |
| 15 | Dredging impact on an urbanized Florida bayou, effects on benthos and algal-periphyton显示文摘 | LEWIS M A WEBER D E STANLEY R S | 2001 | Environmental Pollution2001，115，2： | 1 |
| 16 | Enhancement of calcium signalling dynamics and stability by delayed modulation of the plasmamembrane calcium-ATPase in human T cells 显示文摘 | BAUTISTA D M HOTH M LEWIS R S | 2002 | J Physiol2002，541，3： | 1 |
| 17 | Remifentanil for fetal immobilization and maternal sedation during fetoscopic surgery : A randomized, double-blind comparison with diazepam 显示文摘 | Van de Velde M Schoubroeck D Lewi LE | 2005 | Anesth Analg2005，101，1： | 1 |
| 18 | Joining of aluminum by methods other than fusion welding 显示文摘 | Lewis M D | 1992 | Aluminum Industry1992，11，4： | 1 |
| 19 | Improved cellulose dyeability by chemical modification of the fiber显示文摘 | Lewis D M Lei X P | 1989 | TCC1989，21，10： | 1 |
| 20 | Lighting regimes and plasma LH and FSH in broiler breeders显示文摘 | Lewis P D Ciacciariello M Ciccone N A | 2005 | Br Poult Sei2005，46，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员